- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:06 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics' new year update and seeks shareholders' feedback on proposal to improve shareholder value for their patient capital | 62 | GlobeNewswire (Europe) | SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 13:00 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 08.12.25 | CytoMed: Partnerschaft für klinische Studie in Malaysia treibt Aktie an | 1 | Investing.com Deutsch | ||
| 08.12.25 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology ... | 92 | GlobeNewswire (Europe) | SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 08.12.25 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 18.11.25 | CytoMed acquires TC BioPharm's gamma delta T cell technology | 1 | Investing.com | ||
| 18.11.25 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India | 654 | GlobeNewswire (Europe) | SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| CYTOMED THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.11.25 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.11.25 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 22.10.25 | CytoMed Therapeutics' chairman increases effective holdings to 21.95% | 1 | Seeking Alpha | ||
| 22.10.25 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics' Chairman Increases Effective Holdings to 21.95% | 1 | GlobeNewswire (USA) | ||
| 22.10.25 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 14.10.25 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.10.25 | CytoMed reports promising preclinical results for leukemia treatment | 1 | Investing.com | ||
| 02.10.25 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center | 2 | GlobeNewswire (USA) | ||
| 30.09.25 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.08.25 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 28.08.25 | CYTOMED THERAPEUTICS LIMITED: Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition | 395 | GlobeNewswire (Europe) | SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 19.08.25 | CytoMed Therapeutics plans to raise ~$4.3M via ATM offering | 1 | Seeking Alpha | ||
| 19.08.25 | CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,415 | -1,26 % | QIAGEN - hält was es verspricht | Das Unternehmen aus Hilden hat seine Prognosen im abgelaufenen Geschäftsjahr erreicht. Nun geht es optimistisch in das neue Jahr, in dem es sich auf die Förderung der Produktvermarktung, regulatorische... ► Artikel lesen | |
| BIONTECH | 91,45 | +4,51 % | +23 % Kursplus in wenigen Tagen! DroneShield, BioNTech, WashTec Aktie! | Über 23 % hat die Aktie von DroneShield in den ersten Handelstagen des Jahres bereits zulegen können. Rückenwind erhält der Spezialist für Drohnenabwehr durch zwei Aufträge kurz vor dem Jahreswechsel.... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 78,81 | +13,62 % | Cantor Fitzgerald reiterates Structure Therapeutics stock rating at Overweight | ||
| PRAXIS PRECISION MEDICINES | 275,15 | -0,26 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| ALUMIS | 22,490 | +6,64 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,660 | -2,23 % | Citizens reiterates Market Outperform rating on Summit Therapeutics stock | ||
| ERASCA | 6,710 | +7,70 % | Erasca, Inc.: Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones | Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,350 | +1,73 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio | New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026NDA submission for GIST on track for April 2026; bezuclastinib has the potential to... ► Artikel lesen | |
| EVOTEC | 6,552 | +1,36 % | Evotec Aktie: Das große Comeback im Jahr 2026? | Nächster Anlauf der Evotec Aktie auf große charttechnische Kaufsignale - bisher misslangen diese Ausbruchsversuche. Nachdem die Biotech-Aktie in den letzten Tagen zunächst an der Unterstützung bei 5... ► Artikel lesen | |
| BEAM THERAPEUTICS | 34,060 | +1,10 % | AKTIONÄR-Tipp Beam Therapeutics wie entfesselt: Die Hintergründe! | Innerhalb der Biotech-Branche zählt der Bereich Gen-Schere zu den absoluten Top-Trends. Neben der wohlbekanntesten seiner Klasse, CRISPR/Cas9, entwickeln sich auch andere Ansätze weiter. Dazu zählt... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,37 | +0,02 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,700 | -2,69 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 10,670 | -5,83 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| CG ONCOLOGY | 52,98 | -1,40 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,830 | -3,58 % | Dyne Therapeutics, Inc. - 8-K, Current Report |
CYTOMED THERAPEUTICS LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +7,48 % bei einem Aktienkurs von 1,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTOMED THERAPEUTICS LIMITED finden Sie auf Wallstreet Online.